On May 15, 2019 Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported an upcoming poster presentation at the 2019 ASCO (Free ASCO Whitepaper) Annual Meeting being held in Chicago, May 31 – June 4, 2019 (Press release, Five Prime Therapeutics, MAY 15, 2019, View Source [SID1234536360]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data will be presented from the Phase 1a/1b study of FPA150, which is a first-in-class B7-H4 antibody. The Phase 1a dose escalation portion of the study is being conducted in patients with advanced solid tumors and the Phase 1b expansion is enrolling patients with breast, ovarian and endometrial tumors that overexpress B7-H4.
Here are the details of the upcoming poster presentation:
Poster Title: Phase 1a/1b Study of First-in-class B7-H4 Antibody, FPA150 as Monotherapy in Patients with Advanced Solid Tumors
Abstract Number: 2529
Poster Board: 173
Poster Session: Developmental Immunotherapy and Tumor Immunobiology
Date & Time: Saturday, June 1, 2019, 8:00 – 11:00am
The poster abstracts will be available on May 15, 2019 at 5:00 PM EST at the ASCO (Free ASCO Whitepaper) Meeting Library and the posters can be found on Five Prime Therapeutics’ Scientific Publications page after presentation at the conference.
About FPA150
FPA150 is a novel, fully human, afucosylated monoclonal antibody targeting B7-H4. B7-H4 expression is observed in multiple solid tumors, including breast and gynecologic cancers. FPA150 is designed with a dual mechanism of action: blocking the T cell checkpoint activity of B7-H4 as well as enhanced ADCC against tumor cells expressing B7-H4.